10-K Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 FY 2018

Filing Information

Form Type	10-K
Accession Number	`0001193125-19-043564`
Period End Date	20181231
Filing Date	20190219
Fiscal Year	2018
Fiscal Period	FY
XBRL Instance	teva-20181231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 89 Income Statement 133 Cash Flow Statement 134 Stockholders Equity 28 Comprehensive Income 34

Balance Sheet 89 line items

Line Item	Tag	Value	Unit	Period
Preferred stock par or stated value per share	`PreferredStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Preferred stock par or stated value per share	`PreferredStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	0.00	shares	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	3.70M	shares	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.78B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$963.00M	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$7.13B	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$5.82B	USD	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Inventories	`InventoryNet`	$4.92B	USD	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Inventories	`InventoryNet`	$4.73B	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.10B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.12B	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$899.00M	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$468.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$701.00M	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	107.00M	shares	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$566.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$92.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.79B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.38B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$574.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$368.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$731.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$932.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.87B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$7.67B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$17.64B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$14.01B	USD	Point-in-time
Goodwill	`Goodwill`	$28.41B	USD	Point-in-time
Goodwill	`Goodwill`	$44.41B	USD	Point-in-time
Goodwill	`Goodwill`	$24.92B	USD	Point-in-time
Total assets	`Assets`	$60.68B	USD	Point-in-time
Total assets	`Assets`	$70.61B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.65B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.22B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$6.71B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$7.88B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.07B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.85B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$870.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$549.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.87B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$3.01B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$724.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$804.00M	USD	Point-in-time
Liabilities held for sale	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$38.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.32B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$17.92B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$3.28B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$2.14B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.73B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.84B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$26.70B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$28.83B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$33.95B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$30.57B	USD	Point-in-time
Commitments and contingencies, see note 13	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 13	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$44.89B	USD	Point-in-time
Total liabilities	`Liabilities`	$51.87B	USD	Point-in-time
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; December 31, 2018: no shares authorized or issued; December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares	`PreferredStockValue`	$3.63B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; December 31, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,196 million shares and 1,124 million shares, respectively	`CommonStockValue`	$54.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; December 31, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,196 million shares and 1,124 million shares, respectively	`CommonStockValue`	$56.00M	USD	Point-in-time
Additional paid-incapital	`AdditionalPaidInCapital`	$27.21B	USD	Point-in-time
Additional paid-incapital	`AdditionalPaidInCapital`	$23.48B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-3.80B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-5.96B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.85B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.46B	USD	Point-in-time
Treasury shares as of December 31, 2018 and December 31, 2017: 106 million ordinary shares and 107 million ordinary shares, respectively	`TreasuryStockValue`	$4.15B	USD	Point-in-time
Treasury shares as of December 31, 2018 and December 31, 2017: 106 million ordinary shares and 107 million ordinary shares, respectively	`TreasuryStockValue`	$4.14B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$14.71B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$17.36B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.09B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.39B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.93B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$70.61B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$60.68B	USD	Point-in-time

Income Statement 133 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$5.65B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.70B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$5.72B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$5.40B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$5.07B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$22.39B	USD	Annual
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.53B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$21.90B	USD	Annual
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$18.85B	USD	Annual
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.56B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$5.62B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$10.25B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$11.77B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$10.56B	USD	Annual
Gross profit	`GrossProfit`	$1.97B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.80B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.60B	USD	1 Quarter
Gross profit	`GrossProfit`	$1.98B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.44B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.31B	USD	1 Quarter
Gross profit	`GrossProfit`	$10.62B	USD	Annual
Gross profit	`GrossProfit`	$8.30B	USD	Annual
Gross profit	`GrossProfit`	$2.03B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.77B	USD	1 Quarter
Gross profit	`GrossProfit`	$11.65B	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$2.08B	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$1.21B	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$1.78B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$3.58B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$2.92B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$3.40B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.30B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.45B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.39B	USD	Annual
Intangible assets impairments	`IntangibleAssetsImpairments`	$589.00M	USD	Annual
Intangible assets impairments	`IntangibleAssetsImpairments`	$3.24B	USD	Annual
Intangible assets impairments	`IntangibleAssetsImpairments`	$1.99B	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	$6.10B	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$3.03B	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	$900.00M	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	$11.00B	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$17.10B	USD	Annual
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$830.00M	USD	Annual
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$987.00M	USD	Annual
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$1.84B	USD	Annual
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$500.00M	USD	Annual
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-1.21B	USD	Annual
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$899.00M	USD	Annual
Other income	`OtherIncome`	$769.00M	USD	Annual
Other income	`OtherIncome`	$291.00M	USD	Annual
Other income	`OtherIncome`	$1.20B	USD	Annual
Operating (loss) income	`OperatingIncomeLoss`	$-1.64B	USD	Annual
Operating (loss) income	`OperatingIncomeLoss`	$-17.48B	USD	Annual
Operating (loss) income	`OperatingIncomeLoss`	$2.15B	USD	Annual
Financial expenses-net	`NonoperatingIncomeExpense`	$-959.00M	USD	Annual
Financial expenses-net	`NonoperatingIncomeExpense`	$-1.33B	USD	Annual
Financial expenses-net	`NonoperatingIncomeExpense`	$-895.00M	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-18.38B	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$824.00M	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-2.60B	USD	Annual
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$521.00M	USD	Annual
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-1.93B	USD	Annual
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-195.00M	USD	Annual
Share in (profits) losses of associated companies-net	`IncomeLossFromEquityMethodInvestments`	$-3.00M	USD	Annual
Share in (profits) losses of associated companies-net	`IncomeLossFromEquityMethodInvestments`	$8.00M	USD	Annual
Share in (profits) losses of associated companies-net	`IncomeLossFromEquityMethodInvestments`	$-71.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$311.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$-166.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$641.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-3.24B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-197.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$1.13B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-2.47B	USD	Annual
Net income (loss)	`ProfitLoss`	$-11.73B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-16.45B	USD	Annual
Net income (loss)	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$610.00M	USD	1 Quarter
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-322.00M	USD	Annual
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-18.00M	USD	Annual
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-184.00M	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-5.97B	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-176.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$595.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-208.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-2.89B	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$329.00M	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-2.15B	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-16.27B	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$1.12B	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-11.54B	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$645.00M	USD	1 Quarter
Accrued dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$260.00M	USD	Annual
Accrued dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$249.00M	USD	Annual
Accrued dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$261.00M	USD	Annual
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$1.05B	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$580.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-273.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-2.94B	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-241.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-11.60B	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$530.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-2.40B	USD	Annual
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-16.52B	USD	Annual
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$68.00M	USD	Annual
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-6.04B	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$1.04	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-0.27	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.07	USD	Annual
Basic	`EarningsPerShareBasic`	$0.52	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-11.41	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-0.24	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-2.35	USD	Annual
Basic	`EarningsPerShareBasic`	$-5.94	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-2.85	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.57	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-16.26	USD	Annual
Diluted	`EarningsPerShareDiluted`	$-2.85	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.52	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-11.41	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-2.35	USD	Annual
Diluted	`EarningsPerShareDiluted`	$1.03	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.07	USD	Annual
Diluted	`EarningsPerShareDiluted`	$0.57	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-16.26	USD	Annual
Diluted	`EarningsPerShareDiluted`	$-0.27	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-5.94	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-0.24	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1,016.00	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	955.00	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1,021.00	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1,021.00	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	961.00	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1,016.00	shares	Annual

Cash Flow Statement 134 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$311.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$-166.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$641.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-3.24B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-197.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$1.13B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-2.47B	USD	Annual
Net income (loss)	`ProfitLoss`	$-11.73B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-16.45B	USD	Annual
Net income (loss)	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$610.00M	USD	1 Quarter
Impairment of long-lived assets	`AssetImpairmentCharges`	$5.62B	USD	Annual
Impairment of long-lived assets	`AssetImpairmentCharges`	$1.65B	USD	Annual
Impairment of long-lived assets	`AssetImpairmentCharges`	$20.88B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.52B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$2.11B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.84B	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.65B	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.82B	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$116.00M	USD	Annual
Deferred income taxes-net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-2.33B	USD	Annual
Deferred income taxes-net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$15.00M	USD	Annual
Deferred income taxes-net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-837.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$124.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$133.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$155.00M	USD	Annual
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$135.00M	USD	Annual
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$14.00M	USD	Annual
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-13.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentExpense`	$175.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentExpense`	$422.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentExpense`	$114.00M	USD	Annual
Net loss from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$1.09B	USD	Annual
Net loss from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$19.00M	USD	Annual
Net loss from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$764.00M	USD	Annual
Venezuela deconsolidation loss	`VenezuelaDeconsolidationCharge`	$383.00M	USD	Annual
Venezuela impairment of net monetary assets	`VenezuelaImpairmentOfNetMonetaryAssets`	$42.00M	USD	Annual
Venezuela impairment of net monetary assets	`VenezuelaImpairmentOfNetMonetaryAssets`	$603.00M	USD	Annual
Other-than-temporary impairment	`GainFromRevaluationOfInvestments`	$-140.00M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$3.89B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$2.45B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$2.23B	USD	Annual
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$1.74B	USD	Annual
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$1.33B	USD	Annual
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$1.28B	USD	Annual
Proceeds from sales of long-lived assets and investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$2.00B	USD	Annual
Proceeds from sales of long-lived assets and investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$890.00M	USD	Annual
Proceeds from sales of long-lived assets and investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$3.48B	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$874.00M	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$651.00M	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$901.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$200.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$481.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$119.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$282.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-11.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$212.00M	USD	Annual
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$36.15B	USD	Annual
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$-43.00M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.87B	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$3.45B	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-34.41B	USD	Annual
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$999.00M	USD	Annual
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$3.30B	USD	Annual
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$7.45B	USD	Annual
Proceeds from senior notes and loans, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$506.00M	USD	Annual
Proceeds from senior notes and loans, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$4.43B	USD	Annual
Proceeds from senior notes and loans, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$25.25B	USD	Annual
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-260.00M	USD	Annual
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-1.68B	USD	Annual
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$2.00B	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-74.00M	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-169.00M	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-57.00M	USD	Annual
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$901.00M	USD	Annual
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$12.00M	USD	Annual
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$1.30B	USD	Annual
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStockAndPreferenceStock`	$255.00M	USD	Annual
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStockAndPreferenceStock`	$10.00M	USD	Annual
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStockAndPreferenceStock`	$260.00M	USD	Annual
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	$35.00M	USD	Annual
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	-	USD	Annual
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	-	USD	Annual
Dividends paid to non-controlling interests	`PaymentsOfDividendsMinorityInterest`	$38.00M	USD	Annual
Proceeds from issuance of ordinary shares, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	$329.00M	USD	Annual
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$329.00M	USD	Point-in-time
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$329.00M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-3.35B	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$25.22B	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-5.75B	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-660.00M	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$54.00M	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-142.00M	USD	Annual
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-25.00M	USD	Annual
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$819.00M	USD	Annual
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-5.96B	USD	Annual
Balance of cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.95B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Balance of cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.95B	USD	Point-in-time
Balance of cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$1.36B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$1.29B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$1.72B	USD	Point-in-time
Conversion of mandatory convertible preferred shares into ordinary shares	`ConversionOfStockAmountConverted1`	$3.88B	USD	Annual
Share issuance to Allergan plc for the Actavis Generics acquisition	`SharesIssuedToPurchaseActavisGenerics`	$5.07B	USD	Point-in-time
Shares transferred to Takeda as part of the establishment of Teva Takeda	`SharesTransferredToTakeda`	$-1.82B	USD	Point-in-time
Actavis Generics contingent consideration	`ActavisContingentConsideration`	$302.00M	USD	Point-in-time
Interest	`InterestPaidNet`	$795.00M	USD	Annual
Interest	`InterestPaidNet`	$815.00M	USD	Annual
Interest	`InterestPaidNet`	$290.00M	USD	Annual
Income taxes, net of refunds	`IncomeTaxesPaidNet`	$420.00M	USD	Annual
Income taxes, net of refunds	`IncomeTaxesPaidNet`	$106.00M	USD	Annual
Income taxes, net of refunds	`IncomeTaxesPaidNet`	$341.00M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$658.00M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-1.44B	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-517.00M	USD	Annual
Trade payables, accrued expenses, employee-related obligations and other current liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$-500.00M	USD	Annual
Trade payables, accrued expenses, employee-related obligations and other current liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$-695.00M	USD	Annual
Trade payables, accrued expenses, employee-related obligations and other current liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$-3.08B	USD	Annual
Trade receivables net of sales reserves and allowances	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$343.00M	USD	Annual
Trade receivables net of sales reserves and allowances	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$514.00M	USD	Annual
Trade receivables net of sales reserves and allowances	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$88.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$26.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$370.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$199.00M	USD	Annual
Inventory step-up	`InventoryStepUp`	$-67.00M	USD	Annual
Inventory step-up	`InventoryStepUp`	$-383.00M	USD	Annual
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$-1.65B	USD	Annual
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$-1.82B	USD	Annual
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$-116.00M	USD	Annual

Stockholders Equity 28 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.93B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-953.00M	USD	Annual
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-15.08B	USD	Annual
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-3.06B	USD	Annual
Ordinary shares issuance, value	`StockIssuedDuringPeriodValueNewIssues`	$5.39B	USD	Annual
Ordinary shares issuance, value	`StockIssuedDuringPeriodValueNewIssues`	$-52.00M	USD	Annual
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$4.00M	USD	Annual
MCPS issuance	`MandatoryconvertiblePreferredSharesIssuedDuringPeriodSharesNewIssues`	$329.00M	USD	Annual
Exercise of options by employees and vested RSUs, value	`StockIssuedDuringPeriodValueShareBasedCompensation`	$35.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$159.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$133.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$155.00M	USD	Annual
Dividends to ordinary shareholders	`DividendsCommonStockCash`	$901.00M	USD	Annual
Dividends to ordinary shareholders	`DividendsCommonStockCash`	$1.30B	USD	Annual
Accrued dividends to preferred shareholders	`DividendsPreferredStockCash`	$249.00M	USD	Annual
Accrued dividends to preferred shareholders	`DividendsPreferredStockCash`	$261.00M	USD	Annual
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$111.00M	USD	Annual
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$-1.68B	USD	Annual
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$1.00M	USD	Annual
Other	`OtherEquity`	$-15.00M	USD	Annual
Other	`OtherEquity`	$-40.00M	USD	Annual
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.93B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time

Comprehensive Income 34 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$311.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$-166.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$641.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-3.24B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-197.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$1.13B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-2.47B	USD	Annual
Net income (loss)	`ProfitLoss`	$-11.73B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-16.45B	USD	Annual
Net income (loss)	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$610.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-445.00M	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-713.00M	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.52B	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$140.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-115.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$477.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$3.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-319.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans, net	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$13.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans, net	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-23.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans, net	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-10.00M	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$1.37B	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-1.26B	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-585.00M	USD	Annual
Total comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-953.00M	USD	Annual
Total comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-15.08B	USD	Annual
Total comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-3.06B	USD	Annual
Comprehensive loss attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-296.00M	USD	Annual
Comprehensive loss attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-78.00M	USD	Annual
Comprehensive loss attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-121.00M	USD	Annual
Comprehensive loss attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-14.96B	USD	Annual
Comprehensive loss attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-875.00M	USD	Annual
Comprehensive loss attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-2.76B	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.